Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: A claims database analysis

Diabetes Technology and Therapeutics

Volumn 16, Issue 9, 2014, Pages 567-575

  Xie, Lin ^a   Zhou, Steve ^b   Pinsky, Brett W ^c   Buysman, Erin K ^c   Baser, Onur ^a,d  

^a STATINMED RESEARCH   (United States)

^b SANOFI   (France)

^c OPTUM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIABETIC PATIENT; DISPOSABLE EQUIPMENT; DISPOSABLE PEN; DRUG COST; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN INJECTION PEN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SELF ADMINISTRATION; ECONOMICS; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH INSURANCE; MEDICATION COMPLIANCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; SYRINGE; UNITED STATES;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SELF ADMINISTRATION; SYRINGES; UNITED STATES;

EID: 84906346950     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0312     Document Type: Article

References (33)

1. American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046.
2. Selby JV, Ray GT, Zhang D, Colby CJ: Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-1402.
3. Stephens JM, Botteman MF, Hay JW: Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm 2006;12:130-142.
4. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT: Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-2971.
5. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC: Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285: 182-189.
6. Shetty S, Secnik K, Oglesby AK: Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-564.
7. Heaton A, Martin S, Brelje T: The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003; 16:23-27.
8. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ: Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on longacting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-298.
9. Chen K, Chang EY, Summers KH, Obenchain RL, Yu-Isenberg KS, Sun P: Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. J Manag Care Pharm 2005; 11:376-382.
10. Hall JA, Summers KH, Obenchain RL: Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. J Manag Care Pharm 2003; 9:263-268.
11. Inzucchi SE, Nauck M, Bergenstal RM, Peters AL, Buse JB, Tsapas A, Diamant M, Wender R, Ferrannini E, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 2012;35: 1364-1379.
12. Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, Moffet HH, Marrero DG: Barriers to insulin initiation: the Translating Research Into Action for Diabetes Insulin Starts Project. Diabetes Care 2010;33: 733-735.
13. Korytkowski M, Niskanen L, Asakura T: FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-S100.
14. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW: Patient adherence and medical treatment outcomes: a metaanalysis. Med Care 2002;40:794-811.
15. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O: Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther 2013; 15:230-236.
16. Buysman E, Conner C, Aagren M, Bouchard J, Liu F: Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naive patients with type 2 diabetes. Curr Med Res Opin 2011;27: 1709-1717.
17. Anderson BJ, Redondo MJ: What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol 2011;5:1563-1571.
18. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B: A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009;31:623-631.
19. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-852.
20. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL: Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725.
21. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R: Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294-1305.
22. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr: Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4.
23. Zhao Y, Campbell CR, Fonseca V, Shi L: Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-1132.
24. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. 2008. http://data.bls.gov/ cgi-bin/surveymost?su (accessed January 28, 2011).
25. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
26. Hancu N, Czupryniak L, Genestin E, Sourij H: A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol 2011;5:1224-1234.
27. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE: Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-2805.
28. Wei W, Pan C, Xie L, Baser O: Real-world insulin treatment persistence among patients with type 2 diabetes: measures, predictors and outcomes. Endocr Pract 2014;20:52-61.
29. Lin J, Ling J, Wei W, Pan C: Outcomes of initiating insulin glargine therapy with disposable pen or vial among patients with type 2 diabetes in a U.S. managed care health plan. J Diabetes Sci Technol 2012;6:A90-A91.
30. Saito EP, Davis JW, Harrigan RC, Juarez D, Mau MK. Copayment level and drug switching: findings for type 2 diabetes. Am J Pharm Benefits 2010;2:412-420.
31. Barron J, Wahl P, Fisher M, Plauschinat C: Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. Pharm Ther 2008;33:532-541.
32. Colombi AM, Yu-Isenberg K, Priest J: The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med 2008; 50:535-541.
33. Fendrick AM, Chernew ME: Value-based insurance design: aligning incentives to bridge the divide between quality improvement and cost containment. Am J Manag Care 2006;12(Special Issue):SP5-SP10.